N. Siller

Decreased Cytochrome P450 3A activity in palliative patients with haematological diseases: Potential impact on supportive drug therapies

G. Mikus, H. Bardenheuer, G. Egerer, 2019, Basic & clinical pharmacology & toxicology.

Response to “Can CYP3A Activity Be Evaluated for Drug Interaction Using a Nanogram Dose of Probe Drug?”: Evaluation of CYP3A Activity With Microdoses of Midazolam

W E Haefeli, W. Haefeli, G. Mikus, 2014, Clinical pharmacology and therapeutics.

Normal CYP3A activity during arsenic trioxide therapy

T. Bochtler, G. Mikus, G. Egerer, 2014, Annals of Hematology.

Prolonged sedation of lorazepam due to absent UGT2B4/2B7 glucuronidation

G. Mikus, G. Egerer, J. Weiss, 2013, Archives of Toxicology.